A5044408771- Neuroblastoma Research and Treatments
- Cancer, Hypoxia, and Metabolism
- Sarcoma Diagnosis and Treatment
- Bone Tumor Diagnosis and Treatments
- Lung Cancer Research Studies
- Cancer therapeutics and mechanisms
- Neuroendocrine Tumor Research Advances
- Brain Metastases and Treatment
- Liver physiology and pathology
- Tumors and Oncological Cases
- Chemotherapy-related skin toxicity
- Glioma Diagnosis and Treatment
- Management of metastatic bone disease
- Bone and Joint Diseases
- Neurofibromatosis and Schwannoma Cases
- Pharmacological Receptor Mechanisms and Effects
- Cancer Genomics and Diagnostics
- Reconstructive Surgery and Microvascular Techniques
- CAR-T cell therapy research
- Vascular Tumors and Angiosarcomas
Hospital Sant Joan de Déu Barcelona
2015-2025
Institut de Recerca Sant Joan de Déu
2021
Universidad de Navarra
2009
Naxitamab is an anti-GD2 antibody approved for the treatment of relapsed/refractory HR-NB. We report survival, safety, and relapse pattern a unique set HR-NB patients consolidated with naxitamab after having achieved first CR. Eighty-two were treated 5 cycles GM-CSF days at 250 μg/m2/day (-4 to 0), followed by 500 (1-5) 3 mg/kg/day (1, 3, 5), on outpatient basis. All but one older than 18 months diagnosis had stage M; 21 (25.6%) pts MYCN-amplified (A) NB; 12 (14.6%) detectable MRD in BM....
Patients with high-risk neuroblastoma (HR-NB) who are unable to achieve a complete response (CR) induction therapy have worse outcomes. We investigated the combination of humanized anti-GD2 mAb naxitamab (Hu3F8), irinotecan (I), temozolomide (T), and sargramostim (GM-CSF)-HITS-against primary resistant HR-NB. Eligibility criteria included having measurable chemo-resistant disease at end (EOI) treatment. were excluded if they had progressive (PD) during induction. Prior and/or I/T was...
Naxitamab is a humanized anti-disialoganglioside (GD2) monoclonal antibody approved for treatment of bone/bone marrow refractory high-risk neuroblastoma (HR-NB). Compassionate use (CU) expanded access program at Hospital Sant Joan de Deu permitted patients in complete remission (CR). We here report the survival, toxicity, and relapse pattern first or second CR treated with naxitamab sargramostim (GM-CSF).Seventy-three consecutive HR-NB (stage M age >18 months MYCN-amplified stages L1/L2 any...
Background: Treatment of HR-NB comprise induction, consolidation with autologous stem cell transplant (ASCT) followed by anti-GD2 immunotherapy and isotretinoin. Childrens Oncology Group SIOPEN studies used dinutuximab cytokines to treat patients in complete remission or refractory Bone/Bone marrow (B/BM) disease after ASCT. Methods: referred Hospital Sant Joan de Déu for were eligible two consecutive (dinutuximab EudraCT 2013–004864–69 naxitamab 017–001829–40) naxitamab/Sargramostim CU...
Abstract The goals of this work were to identify factors favoring patient‐derived xenograft (PDX) engraftment and study the association between PDX prognosis in pediatric patients with Ewing sarcoma, osteosarcoma, rhabdomyosarcoma. We used immunodeficient mice establish 30 subcutaneous from patient tumor biopsies, a successful rate 44%. Age greater than 12 years relapsed disease associated higher rate. Tumor type biopsy location did not associate engraftment. models retained histology...
Background: Neuroblastic tumors (NBTs) originate from a block in the process of differentiation. Histologically, NBTs are classified neuroblastoma (NB), ganglioneuroblastoma (GNB), and ganglioneuroma (GN). Current therapy for high-risk (HR) NB includes chemotherapy, surgery, radiotherapy, anti-GD2 monoclonal antibodies (mAbs). Anti-GD2 mAbs induce immunological cytoxicity but also direct cell death. Methods: We report on patients treated with naxitamab chemorefractory showing lesions long...
Neuroblastoma presents with two patterns of disease: locoregional or systemic. The poor prognostic risk factors neuroblastoma (LR-NB) include age, MYCN MDM2-CDK4 amplification, 11q, histology, diploidy ALK TERT mutations, and ATRX aberrations. Anti-GD2 immunotherapy has significantly improved the outcome high-risk (HR) NB is mostly effective against osteomedullary minimal residual disease (MRD), but less so soft tissue disease. question whether adding anti-GD2 monoclonal antibodies (mAbs)...
10025 Background: Chemoresistant and relapsed disease are major obstacles to curing high-risk neuroblastoma (HR-NB). Anti-GD2 monoclonal antibody (MoAb) is effective in preventing relapse after remission but responses or progressive (PD) rare. We investigated the combination of humanized anti-GD2 MoAb naxitamab, (previously termed Hu3F8), irinotecan, temozolomide sargramostim (GM-CSF): a pilot HITS protocol against resistant HR-NB now expanded phase II study (NCT03189706). Methods: Salient...
10037 Background: Patients with relapsed/refractory (R/R) high-risk neuroblastoma (HR-NB) have dismal prognosis chemotherapy-only salvage regimens. Naxitamab, a humanized anti-GD2 monoclonal antibody (mAb), when combined Irinotecan and Temozolomide (I/T), has demonstrated clinically meaningful efficacy in R/R HR-NB patients (NCT03189706). We aimed to investigate the potential synergy of naxitamab other cytotoxics. Methods: In this retrospective analysis, we examined treated at SJD...
Radiation recall reaction (RRR) is a rare inflammatory developing in previously irradiated field after triggering agent. In pediatric patients, it poorly understood and deficiently studied. Gemcitabine-docetaxel (G/D) childhood cancer mainly used as salvage regimen for sarcomas. We aim to describe RRR triggered by G/D children.
10539 Background: Treatment of high-risk NB within the major international cooperative groups (COG and SIOP) comprise intensive induction, consolidation with high dose chemotherapy autologous stem cell rescue (ASCR) followed by anti-GD2 immunotherapy isotretinoin as maintenance therapy. In COG studies dinutuximab cytokines (GM-CSF IL-2) were used to treat patients in complete remission (CR) after ASCR whereas SIOPEN dinutuximab-beta plus/minus IL-2 included responsive (no progression 109...